Literature DB >> 32105714

Estimating Resource Utilization in Congenital Heart Surgery.

Sara K Pasquali1, Karen Chiswell2, Matt Hall3, Dylan Thibault2, Jennifer C Romano4, J William Gaynor5, David M Shahian6, Marshall L Jacobs7, Michael G Gaies8, Sean M O'Brien2, Edward C Norton9, Kevin D Hill2, Patricia A Cowper2, Nelangi M Pinto10, Samir S Shah11, John E Mayer12, Jeffrey P Jacobs13.   

Abstract

BACKGROUND: Optimal methods to assess resource utilization in congenital heart surgery remain unclear. We compared traditional cost-to-charge ratio methods with newer standardized cost methods that aim to more directly assess resources consumed.
METHODS: Clinical data from The Society of Thoracic Surgeons Database were linked with resource use data from the Pediatric Health Information Systems Database (2010 to 2015). Standardized cost methods specific to the congenital heart surgery population were developed and compared with cost-to-charge ratio methods. Resource use in the overall population and variability across hospitals were described using hierarchical mixed effect models adjusting for case-mix.
RESULTS: Overall, 43 hospitals (65,331 patients) were included. There were minimal population-level differences in the distribution of resource use as estimated by the two methods. At the hospital level, there was less apparent variability in resource use across centers with the standardized cost vs cost-to-charge ratio method, overall (coefficient of variation 20% vs 25%) and across complexity (The Society of Thoracic Surgeons-European Association for Cardiothoracic Surgery [STAT]) categories. When hospitals were categorized into tertiles by resource use, 33% changed classification depending on which resource use method was used (26% by one tertile and 7% by two tertiles).
CONCLUSIONS: In this first evaluation of standardized cost methodology in the congenital heart population, we found minimal differences vs traditional methods at the population level. At the hospital level, the magnitude of variation in resource use was less with standardized cost methods, and approximately one third of centers changed resource use categories depending on the methodology used. Because of these differences, care should be taken in future studies and in benchmarking and reporting efforts in selecting optimal methodology.
Copyright © 2020 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32105714      PMCID: PMC8237745          DOI: 10.1016/j.athoracsur.2020.01.013

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  14 in total

1.  Assessment of Costs in Congenital Heart Surgery.

Authors:  Sara K Pasquali; Marshall L Jacobs
Journal:  World J Pediatr Congenit Heart Surg       Date:  2014-07

2.  Observation-status patients in children's hospitals with and without dedicated observation units in 2011.

Authors:  Michelle L Macy; Matthew Hall; Elizabeth R Alpern; Evan S Fieldston; Leticia A Shanley; Carla Hronek; Paul D Hain; Samir S Shah
Journal:  J Hosp Med       Date:  2015-03-05       Impact factor: 2.960

3.  Prioritization of comparative effectiveness research topics in hospital pediatrics.

Authors:  Ron Keren; Xianqun Luan; Russell Localio; Matt Hall; Lisa McLeod; Dingwei Dai; Rajendu Srivastava
Journal:  Arch Pediatr Adolesc Med       Date:  2012-12

4.  Quality-Cost Relationship in Congenital Heart Surgery.

Authors:  Sara K Pasquali; Jeffrey P Jacobs; Edward L Bove; J William Gaynor; Xia He; Michael G Gaies; Jennifer C Hirsch-Romano; John E Mayer; Eric D Peterson; Nelangi M Pinto; Samir S Shah; Matt Hall; Marshall L Jacobs
Journal:  Ann Thorac Surg       Date:  2015-07-14       Impact factor: 4.330

5.  Cost Variation Across Centers for the Norwood Operation.

Authors:  Kimberly E McHugh; Sara K Pasquali; Matthew A Hall; Mark A Scheurer
Journal:  Ann Thorac Surg       Date:  2017-12-07       Impact factor: 4.330

6.  Linking clinical registry data with administrative data using indirect identifiers: implementation and validation in the congenital heart surgery population.

Authors:  Sara K Pasquali; Jeffrey P Jacobs; Gregory J Shook; Sean M O'Brien; Matthew Hall; Marshall L Jacobs; Karl F Welke; J William Gaynor; Eric D Peterson; Samir S Shah; Jennifer S Li
Journal:  Am Heart J       Date:  2010-12       Impact factor: 4.749

7.  Hospital stays, hospital charges, and in-hospital deaths among infants with selected birth defects--United States, 2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-01-19       Impact factor: 17.586

8.  An empirically based tool for analyzing mortality associated with congenital heart surgery.

Authors:  Sean M O'Brien; David R Clarke; Jeffrey P Jacobs; Marshall L Jacobs; Francois G Lacour-Gayet; Christian Pizarro; Karl F Welke; Bohdan Maruszewski; Zdzislaw Tobota; Weldon J Miller; Leslie Hamilton; Eric D Peterson; Constantine Mavroudis; Fred H Edwards
Journal:  J Thorac Cardiovasc Surg       Date:  2009-11       Impact factor: 5.209

9.  Influence of Time to Appendectomy and Operative Duration on Hospital Cost in Children with Uncomplicated Appendicitis.

Authors:  Stephanie K Serres; Dionne A Graham; Charity C Glass; Danielle B Cameron; Seema P Anandalwar; Shawn J Rangel
Journal:  J Am Coll Surg       Date:  2017-11-16       Impact factor: 6.113

10.  The Society of Thoracic Surgeons Congenital Heart Surgery Database Mortality Risk Model: Part 1-Statistical Methodology.

Authors:  Sean M O'Brien; Jeffrey P Jacobs; Sara K Pasquali; J William Gaynor; Tara Karamlou; Karl F Welke; Giovanni Filardo; Jane M Han; Sunghee Kim; David M Shahian; Marshall L Jacobs
Journal:  Ann Thorac Surg       Date:  2015-08-03       Impact factor: 4.330

View more
  1 in total

1.  An integrated analysis of the competing endogenous RNA network associated of prognosis of stage I lung adenocarcinoma.

Authors:  Yuan Xu; Guofu Lin; Yifei Liu; Xianbin Lin; Hai Lin; Zhifeng Guo; Yingxuan Xu; Qinhui Lin; Shaohua Chen; Jiansheng Yang; Yiming Zeng
Journal:  BMC Cancer       Date:  2022-02-19       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.